Quantcast

Latest CytoSorbents Corporation Stories

2014-08-12 16:27:59

MONMOUTH JUNCTION, N.J., Aug. 12, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat critically-ill patients in multiple countries worldwide, reported second quarter financial and operational results for the three and six months ended June 30, 2014. http://photos.prnewswire.com/prnvar/20140408/MM00899LOGO Q2 2014 Total Revenue of $1.0M, Driven by Record CytoSorb® sales of $663K....

2014-08-06 08:34:00

MONMOUTH JUNCTION, N.J., Aug. 6, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q2 2014 financial results after the market close on Tuesday, August 12, 2014. http://photos.prnewswire.com/prnvar/20140408/MM00899LOGO CytoSorbents' management will host a live conference call and presentation...

2014-08-05 08:32:08

MONMOUTH JUNCTION, N.J., Aug. 5, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced distribution of its CytoSorb(®) extracorporeal cytokine adsorber in Taiwan through an exclusive agreement with Hemoscien Corporation. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb(®) to maintain exclusivity....

2014-07-17 08:25:12

MONMOUTH JUNCTION, N.J., July 17, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany....

2014-07-09 08:28:26

MONMOUTH JUNCTION, N.J., July 9, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced consolidation of its SEC and international legal counsel with the global law firm, DLA Piper LLP. DLA Piper is one of the largest international business law firms with offices in major markets around the world and legal expertise across a broad range of areas including corporate and...

2014-05-14 16:28:19

MONMOUTH JUNCTION, N.J., May 14, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, reports first quarter operational and financial results for the three months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20140408/MM00899LOGO Achieved record total revenue and CytoSorb® sales of $1.1M and $569,000, respectively, in Q1 2014 with continued strong momentum expected in Q2...

2014-05-08 08:31:33

MONMOUTH JUNCTION, N.J., May 8, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q1 2014 financial results after the market close on Wednesday, May 14, 2014. http://photos.prnewswire.com/prnvar/20140408/MM00899LOGO CytoSorbents' management will host a live conference call and presentation...

2014-04-03 08:30:31

MONMOUTH JUNCTION, N.J., April 3, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life threatening conditions in the intensive care unit, announced that Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents, will present a corporate overview at the 13(th) Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York City, New York. Dr. Chan will present from 10:00...

2014-03-31 16:27:14

MONMOUTH JUNCTION, N.J., March 31, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013. Q1 2014 CytoSorb® product revenue guidance in the range of $530,000 - $570,000 represents more than 60% of total 2013 CytoSorb® revenues Highlights for the Year Ending...

2014-03-25 08:28:57

MONMOUTH JUNCTION, N.J., March 25, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report fiscal 2013 financial results after the market close on Monday, March 31, 2014. CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related